Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Overview

Journal Brain Sci

Publisher MDPI

Date 2020 Oct 21

PMID 33081261

Citations 20

Authors

Samskruthi Madireddy

Sahithi Madireddy

Affiliations

Soon will be listed here.

Abstract

The biochemical integrity of the brain is paramount to the function of the central nervous system, and oxidative stress is a key contributor to cerebral biochemical impairment. Oxidative stress, which occurs when an imbalance arises between the production of reactive oxygen species (ROS) and the efficacy of the antioxidant defense mechanism, is believed to play a role in the pathophysiology of various brain disorders. One such disorder, schizophrenia, not only causes lifelong disability but also induces severe emotional distress; however, because of its onset in early adolescence or adulthood and its progressive development, consuming natural antioxidant products may help regulate the pathogenesis of schizophrenia. Therefore, elucidating the functions of ROS and dietary antioxidants in the pathogenesis of schizophrenia could help formulate improved therapeutic strategies for its prevention and treatment. This review focuses specifically on the roles of ROS and oxidative damage in the pathophysiology of schizophrenia, as well as the effects of nutrition, antipsychotic use, cognitive therapies, and quality of life on patients with schizophrenia. By improving our understanding of the effects of various nutrients on schizophrenia, it may become possible to develop nutritional strategies and supplements to treat the disorder, alleviate its symptoms, and facilitate long-term recovery.

Citing Articles

The Preventive Effect of Zinc Sulfate against Olanzapine-Induced Testicular Toxicity in Male Rats.

Ebaid H, Bashandy S, Hassan I, Al-Tamimi J, Haredy S, Imbabi T Biol Trace Elem Res. 2024; .

PMID: 39653981 DOI: 10.1007/s12011-024-04442-8.

Neuroinflammation and Brain Health Risks in Veterans Exposed to Burn Pit Toxins.

Brooks A, Sandri B, Nixon J, Nurkiewicz T, Barach P, Trembley J Int J Mol Sci. 2024; 25(18).

PMID: 39337247 PMC: 11432193. DOI: 10.3390/ijms25189759.

Transgenic Carrying a Human Full-Length DISC1 Construct (UAS-) Showing Effects on Social Interaction Networks.

Samardzija B, Petrovic M, Zaharija B, Medija M, Mestrovic A, Bradshaw N Curr Issues Mol Biol. 2024; 46(8):8526-8549.

PMID: 39194719 PMC: 11352338. DOI: 10.3390/cimb46080502.

Neuroprotective potential of Afzelin: A novel approach for alleviating catalepsy and modulating Bcl-2 expression in Parkinson's disease therapy.

Alharthy K, Rashid S, Yusufoglu H, Alqasoumi S, Ganaie M, Alam A Saudi Pharm J. 2024; 32(2):101928.

PMID: 38261905 PMC: 10797200. DOI: 10.1016/j.jsps.2023.101928.

Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation.

Madireddy S, Madireddy S Brain Sci. 2023; 13(5).

PMID: 37239256 PMC: 10216584. DOI: 10.3390/brainsci13050784.

References

Miljevic C, Nikolic-Kokic A, Blagojevic D, Milovanovic M, Munjiza A, Jukic M . Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res. 2018; 269:746-752. DOI: 10.1016/j.psychres.2018.09.009. View

Forni C, Facchiano F, Bartoli M, Pieretti S, Facchiano A, DArcangelo D . Beneficial Role of Phytochemicals on Oxidative Stress and Age-Related Diseases. Biomed Res Int. 2019; 2019:8748253. PMC: 6475554. DOI: 10.1155/2019/8748253. View

Dipasquale S, Pariante C, Dazzan P, Aguglia E, McGuire P, Mondelli V . The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2012; 47(2):197-207. DOI: 10.1016/j.jpsychires.2012.10.005. View

Khokhar J, Henricks A, Sullivan E, Green A . Unique Effects of Clozapine: A Pharmacological Perspective. Adv Pharmacol. 2018; 82:137-162. PMC: 7197512. DOI: 10.1016/bs.apha.2017.09.009. View

Zhu J, Luo W, Cheng X, Li Y, Zhang Q, Peng W . Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. Psychiatry Res. 2020; 288:112959. DOI: 10.1016/j.psychres.2020.112959. View

Wang D, Zhai J, Liu D . Serum folate levels in schizophrenia: A meta-analysis. Psychiatry Res. 2015; 235:83-9. DOI: 10.1016/j.psychres.2015.11.045. View

Avval F, Mahmoudi N, Nosrati Tirkani A, Jarahi L, Alamdari D, Sadjadi S . Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia. Iran J Psychiatry. 2018; 13(3):222-226. PMC: 6178326. View

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

Jordan W, Dobrowolny H, Bahn S, Bernstein H, Brigadski T, Frodl T . Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci. 2016; 268(2):129-143. DOI: 10.1007/s00406-016-0749-7. View

10.

Das S, Barnwal P, Winston A B, Mondal S, Saha I . Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016; 6(1):39-54. PMC: 4749739. DOI: 10.1177/2045125315614739. View

11.

Tessier C, Sweers K, Frajerman A, Bergaoui H, Ferreri F, Delva C . Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations. Transl Psychiatry. 2016; 6(10):e906. PMC: 5315538. DOI: 10.1038/tp.2016.142. View

12.

Frampton J . Brexpiprazole: A Review in Schizophrenia. Drugs. 2019; 79(2):189-200. DOI: 10.1007/s40265-019-1052-5. View

13.

Wu J, Kosten T, Zhang X . Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:200-6. DOI: 10.1016/j.pnpbp.2013.02.015. View

14.

Albayrak Y, Unsal C, Beyazyuz M, Unal A, Kuloglu M . Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:144-9. DOI: 10.1016/j.pnpbp.2013.04.020. View

15.

Agostoni C, Nobile M, Ciappolino V, Delvecchio G, Tesei A, Turolo S . The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD. Int J Mol Sci. 2017; 18(12). PMC: 5751211. DOI: 10.3390/ijms18122608. View

16.

An H, Du X, Huang X, Qi L, Jia Q, Yin G . Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl Psychiatry. 2018; 8(1):258. PMC: 6265271. DOI: 10.1038/s41398-018-0303-7. View

17.

Salim S . Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther. 2016; 360(1):201-205. PMC: 5193071. DOI: 10.1124/jpet.116.237503. View

18.

Siskind D, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B . Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018; 52(8):751-767. DOI: 10.1177/0004867418772351. View

19.

Dean O, van den Buuse M, Bush A, Copolov D, Ng F, Dodd S . A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem. 2009; 16(23):2965-76. DOI: 10.2174/092986709788803060. View

20.

Maas D, Valles A, Martens G . Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry. 2017; 7(7):e1171. PMC: 5538118. DOI: 10.1038/tp.2017.138. View